AMRX Amneal Pharmaceuticals, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1723128 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY8.9%
TTM net income YoY2,159.3%
TTM EPS YoY3,900.0%
Revenue 3-yr CAGR10.2%
Net income 3-yr CAGR270.1%
Margins
Gross margin40.2%
Operating margin15.0%
Net margin4.2%
FCF margin2.8%
EBITDA margin—
Returns
ROE63.2%
ROA3.0%
ROIC (approx.)16.3%
Asset turnover0.72x
Leverage & solvency
Liabilities / assets87.8%
Debt / equity5.53x
Current ratio1.87x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.36x
Accruals ratio-1.1%
Payout ratio—
Capex / revenue2.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $862.68M | $796.20M | $722.52M | $814.32M | $784.51M | $724.51M | $695.42M | $730.52M |
| Cost of revenue | $528.57M | $461.69M | $402.41M | $517.13M | $510.54M | $438.25M | $439.53M | $467.64M |
| Gross profit | $334.12M | $334.51M | $320.11M | $297.19M | $273.97M | $286.25M | $255.89M | $262.87M |
| R&D expense | $68.37M | $39.02M | $38.38M | $34.82M | $63.35M | $47.96M | $40.04M | $54.27M |
| SG&A expense | $139.65M | $148.72M | $138.86M | $146.46M | $137.81M | $124.27M | $118.29M | $128.69M |
| Operating income | $95.42M | $129.77M | $141.77M | $112.03M | $70.34M | $111.37M | $100.35M | $75.79M |
| Pretax income | $15.06M | $70.99M | $80.18M | $55.23M | -$5.22M | $51.71M | $37.49M | -$15.32M |
| Income tax | $2.75M | $1.38M | $2.18M | $5.66M | -$23.36M | $16.10M | $12.87M | $5.42M |
| Net income | -$21.70M | $57.66M | $62.26M | $35.08M | $2.37M | $22.42M | $12.20M | -$31.08M |
| EBITDA | $110.11M | — | — | $125.63M | $84.84M | — | — | — |
| EPS (basic) | -0.06 | 0.18 | 0.20 | — | 0.01 | 0.07 | 0.04 | — |
| EPS (diluted) | -0.06 | 0.18 | 0.19 | — | 0.01 | 0.07 | 0.04 | — |
| Weighted avg. shares (diluted) | 335.73M | 328.10M | 328.93M | — | 324.75M | 322.36M | 323.96M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $157.40M | $127.64M | $197.66M | $282.03M | $201.25M | $71.54M | $59.19M | $118.42M |
| Inventory | $707.96M | $677.95M | $641.62M | $606.30M | $614.50M | $608.97M | $601.43M | $612.45M |
| Current assets | $2.10B | $1.95B | $1.80B | $1.91B | $1.84B | $1.58B | $1.51B | $1.59B |
| PP&E, net | $572.63M | $456.88M | $444.61M | $442.95M | $434.99M | $440.33M | $427.23M | $424.91M |
| Goodwill | $772.47M | $593.50M | $593.80M | $595.47M | $595.95M | $597.41M | $597.50M | $597.44M |
| Intangibles | $1.55B | $587.83M | $534.87M | $563.50M | $587.94M | $649.55M | $689.14M | $732.38M |
| Total assets | $5.27B | $3.78B | $3.54B | $3.68B | $3.60B | $3.42B | $3.37B | $3.50B |
| Current liabilities | $1.12B | $883.19M | $728.05M | $881.63M | $862.11M | $1.11B | $1.08B | $1.13B |
| Short-term debt | $23.93M | $5.96M | $6.20M | $6.76M | $7.20M | $31.18M | $31.79M | $224.21M |
| Long-term debt | $2.92B | $2.56B | $2.57B | $2.57B | $2.57B | $2.15B | $2.15B | $2.16B |
| Total debt | $2.94B | $2.57B | $2.57B | $2.57B | $2.57B | $2.18B | $2.19B | $2.39B |
| Total liabilities | $4.63B | $3.66B | $3.50B | $3.67B | $3.64B | $3.47B | $3.42B | $3.55B |
| Shareholders' equity | $531.26M | $33.02M | -$45.41M | -$70.79M | -$109.46M | -$112.12M | -$131.67M | -$109.27M |
| Net debt | $2.78B | $2.44B | $2.37B | $2.29B | $2.37B | $2.11B | $2.13B | $2.27B |
| Cash flow statement | ||||||||
| Operating cash flow | $98.30M | -$21.24M | -$26.74M | $130.31M | $118.45M | $83.82M | $7.41M | $118.08M |
| Capital expenditure | $31.79M | $30.70M | $8.18M | $21.77M | $12.30M | $22.83M | $13.16M | $15.15M |
| Free cash flow | $66.51M | -$51.94M | -$34.92M | $108.54M | $106.15M | $60.99M | -$5.75M | $102.92M |
| Investing cash flow | -$472.23M | -$122.74M | -$21.71M | -$45.45M | -$22.46M | -$26.55M | -$17.80M | -$16.06M |
| Financing cash flow | $415.19M | $79.36M | -$59.05M | -$10.12M | $59.44M | -$41.69M | -$39.17M | -$61.20M |
| Depreciation & amortization | $14.70M | — | — | $13.60M | $14.50M | — | — | — |
| Stock-based compensation | $10.52M | $10.39M | $8.82M | $8.20M | $8.22M | $8.27M | $7.26M | $7.21M |
Free plan shows the latest 8 periods; Pro shows all 40 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.